WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and management’s participation are as follows:

H.C. Wainwright BioConnect 2022



Dates: January 10-13, 2022

Format: On-demand investor presentation beginning on January 10, 1-on-1 investor meetings

Fireside Chat: January 10, with link available through the event portal

Registration:

www.hcwevents.com/bioconnect

About Entasis


Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting

Acinetobacter baumannii

infections), zoliflodacin (targeting

Neisseria gonorrhoeae

infections), ETX0462 (targeting multiple Gram-negative pathogens including

Pseudomonas aeruginosa

) and ETX0282CPDP (targeting

Enterobacteriaceae

infections). For more information, visit

www.entasistx.com

.